Published in J Natl Cancer Inst on August 08, 2007
Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol (2009) 3.43
Cardiotoxicity of anticancer treatments. Nat Rev Cardiol (2015) 2.28
Platelets, petechiae, and preservation of the vascular wall. N Engl J Med (2008) 2.25
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol (2008) 2.03
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol (2010) 1.80
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) (2013) 1.67
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc (2012) 1.46
Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol (2012) 1.41
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol (2009) 1.38
Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer (2011) 1.36
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol (2010) 1.27
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer (2010) 1.23
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis (2009) 1.20
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol (2009) 1.11
Drug-induced hematologic syndromes. Adv Hematol (2009) 1.11
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer (2010) 1.10
Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw (2012) 1.09
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist (2011) 1.08
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol (2009) 1.07
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol (2010) 1.06
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer (2010) 1.05
Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res (2009) 1.04
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Management of antiangiogenic therapy-induced hypertension. Hypertension (2012) 1.02
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology (2013) 1.01
The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist (2010) 1.00
Clinical pharmacology of cancer therapies in older adults. Br J Cancer (2008) 1.00
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ (2012) 1.00
Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol (2012) 1.00
Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation. NDT Plus (2008) 0.99
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol (2011) 0.99
The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol (2009) 0.97
Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist (2010) 0.96
Vascular complications and diabetes: current therapies and future challenges. J Ophthalmol (2012) 0.95
Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist (2011) 0.95
Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag (2008) 0.94
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med (2013) 0.94
Stroke and Cancer- A Complicated Relationship. J Neurol Transl Neurosci (2015) 0.93
Treatment-related mortality with aflibercept in cancer patients: a meta-analysis. Eur J Clin Pharmacol (2014) 0.93
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol (2012) 0.93
Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). Protein Eng Des Sel (2013) 0.92
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer (2014) 0.92
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.92
Colorectal cancer and hypercoagulability. Surg Today (2013) 0.92
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol (2015) 0.90
Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol (2013) 0.90
Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist (2013) 0.90
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol (2011) 0.89
Targeted therapies in epithelial ovarian cancer. J Oncol (2010) 0.89
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One (2012) 0.89
Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol (2012) 0.89
Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol (2015) 0.88
Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol (2013) 0.86
Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer (2010) 0.86
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health (2016) 0.85
Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS One (2014) 0.85
Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma. Gastroenterol Res Pract (2011) 0.85
Cardiac effects of anticancer therapy in the elderly. J Clin Oncol (2014) 0.84
Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res (2015) 0.84
Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother (2013) 0.84
Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors. Invest New Drugs (2009) 0.84
Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One (2014) 0.83
Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging (2011) 0.83
Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol (2015) 0.83
Vascular Toxicities of Cancer Therapies: The Old and the New - An Evolving Avenue. Circulation (2016) 0.82
Bevacizumab for glioblastoma. Ther Clin Risk Manag (2015) 0.81
Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. Atherosclerosis (2015) 0.81
The effect of bevacizumab on corneal neovascularization in rabbits. Korean J Ophthalmol (2010) 0.81
Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean J Ophthalmol (2009) 0.80
Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol (2011) 0.80
Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int (2015) 0.80
Cancer and coagulation. Am J Hematol (2012) 0.80
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol (2014) 0.80
Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res (2014) 0.80
Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist (2015) 0.80
Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador. Curr Oncol (2010) 0.80
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab. J Korean Med Sci (2012) 0.79
Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.79
Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol (2008) 0.79
Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res (2008) 0.79
Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Med (2013) 0.79
Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. Exp Transl Stroke Med (2013) 0.79
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. World J Gastroenterol (2011) 0.79
Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am (2012) 0.79
Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res (2012) 0.79
The Crossroads of Geriatric Cardiology and Cardio-Oncology. Curr Geriatr Rep (2015) 0.78
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco Targets Ther (2009) 0.78
Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage? World J Gastroenterol (2013) 0.78
Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. Biomed Res Int (2013) 0.78
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell (2006) 3.10
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2002) 2.89
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol (2005) 2.47
Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc (2003) 2.32
Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin. FASEB J (2007) 2.30
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol (2009) 2.18
Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation (2002) 2.15
Use of molecular biomarkers to inform adjuvant therapy for colon cancer. Oncology (Williston Park) (2013) 2.07
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem (2002) 2.02
Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development (2005) 1.93
Neuroendocrine tumors. J Natl Compr Canc Netw (2012) 1.91
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res (2013) 1.89
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension (2009) 1.88
Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell (2012) 1.79
A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A (2014) 1.77
Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg (2005) 1.71
Partner-assisted emotional disclosure for patients with gastrointestinal cancer: results from a randomized controlled trial. Cancer (2009) 1.68
Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology (2010) 1.62
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood (2004) 1.62
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer (2008) 1.58
Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost (2004) 1.55
Endpoints for agents that slow tumor growth. Contemp Clin Trials (2006) 1.52
Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Dev Biol (2007) 1.51
Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw (2015) 1.51
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol (2008) 1.40
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer (2003) 1.40
Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. Physiol Genomics (2004) 1.40
Rat-to-elephant-to-human transmission of cowpox virus. Emerg Infect Dis (2008) 1.40
Noninvasive metabolomic profiling of human embryo culture media using Raman spectroscopy predicts embryonic reproductive potential: a prospective blinded pilot study. Fertil Steril (2008) 1.39
Disclosure between patients with gastrointestinal cancer and their spouses. Psychooncology (2005) 1.38
Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res (2006) 1.29
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol (2007) 1.25
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res (2008) 1.22
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist (2013) 1.19
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19
Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer (2010) 1.18
The forming limb skeleton serves as a signaling center for limb vasculature patterning via regulation of Vegf. Development (2009) 1.16
The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res (2005) 1.12
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist (2008) 1.11
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res (2008) 1.11
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood (2007) 1.09
Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics (2008) 1.08
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.08
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol (2014) 1.05
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int (2010) 1.03
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther (2012) 1.01
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer (2011) 1.01
Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol (2003) 1.01
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer (2012) 1.01
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol (2003) 1.01
Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm (2013) 1.00
An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies. Contemp Clin Trials (2007) 1.00
Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs (2011) 0.99
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther (2008) 0.99
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology (2005) 0.98
Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol (2012) 0.98
Application of a facial injury severity scale in craniomaxillofacial trauma. J Oral Maxillofac Surg (2006) 0.97
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs (2009) 0.97
Functional and oncological outcomes of partial nephrectomy of solitary kidneys. J Urol (2009) 0.96
Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther (2008) 0.95